Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3

Diabetes

Volumn 61, Issue 4, 2012, Pages 797-806

  Li, Huating ^a,b   Gao, Zhanguo ^c   Zhang, Jin ^c   Ye, Xin ^c   Xu, Aimin ^d   Ye, Jianping ^c   Jia, Weiping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; BUTYRIC ACID; FATTY ACID; FENOFIBRATE; FIBROBLAST GROWTH FACTOR 21; HISTONE DEACETYLASE 3; KETONE BODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN ANTIBODY; TRICHOSTATIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INHIBITION; FATTY ACID OXIDATION; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN CELL; KETOGENESIS; KNOCKOUT MOUSE; LIVER; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SERODIAGNOSIS;

ANIMALS; BEZAFIBRATE; BUTYRATES; DIETARY FATS; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HEK293 CELLS; HEP G2 CELLS; HISTONE DEACETYLASES; HUMANS; HYPOLIPIDEMIC AGENTS; LIVER; MALE; MICE; MICE, KNOCKOUT; MICE, OBESE; OBESITY; PPAR ALPHA; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 84859529243     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0846     Document Type: Article

References (32)

1. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004;20:563-569 (Pubitemid 39314564)
2. Kharitonenkov A, Larsen P. FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol Metab 2011;22:81-86
3. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115:1627-1635 (Pubitemid 40814671)
4. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007;5: 426-437 (Pubitemid 46825495)
5. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009;150:4931-4940
6. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008;149:6018-6027
7. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57:1246-1253
8. Gälman C, Lundåsen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008;8:169-174
9. Li H, Bao Y, Xu A, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009;94: 2151-2156
10. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009;32:1542-1546
11. Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010;53:934-940
12. Berglund ED, Li CY, Bina HA, et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009;150:4084-4093
13. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010;59:2781-2789
14. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007;5:415-425 (Pubitemid 46825496)
15. Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab 2009;94: 3594-3601
16. Oishi K, Tomita T. Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver. Biol Pharm Bull 2011;34:1120-1121
17. Gao Z, Yin J, Zhang J, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009;58:1509-1517
18. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003;133(Suppl.):2485S-2493S (Pubitemid 36828858)
19. Bryzgalova G, Effendic S, Khan A, et al. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol 2008;111:262-267
20. Grover GJ, Mellström K, Malm J. Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlipidemia and diabetes. Curr Vasc Pharmacol 2007;5:141-154
21. Sewack GF, Ellis TW, Hansen U. Binding of TATA binding protein to a naturally positioned nucleosome is facilitated by histone acetylation. Mol Cell Biol 2001;21:1404-1415 (Pubitemid 32114987)
22. Mihaylova MM, Vasquez DS, Ravnskjaer K, et al. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 2011;145:607-621
23. Hotta Y, Nakamura H, Konishi M, et al. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 2009;150:4625-4633
24. Clemenz M, Frost N, Schupp M, et al. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008;57:1405-1413
25. Drynan L, Quant PA, Zammit VA. Flux control exerted by mitochondrial outer membrane carnitine palmitoyltransferase over beta-oxidation, ketogenesis and tricarboxylic acid cycle activity in hepatocytes isolated from rats in different metabolic states. Biochem J 1996;317:791-795
26. Hegardt FG. Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: a control enzyme in ketogenesis. Biochem J 1999;338:569-582 (Pubitemid 29140059)
27. Mai K, Andres J, Biedasek K, et al. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009;58:1532-1538
28. Yu H, Xia F, Lam KS, et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem 2011;57:691-700
29. Adams AC, Astapova I, Fisher FM, et al. Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner. J Biol Chem 2010;285:14078-14082
30. Litherland NB, Bionaz M, Wallace RL, Loor JJ, Drackley JK. Effects of the peroxisome proliferator-activated receptor-alpha agonists clofibrate and fish oil on hepatic fatty acid metabolism in weaned dairy calves. J Dairy Sci 2010;93:2404-2418
31. Muoio DM, Way JM, Tanner CJ, et al. Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 2002;51:901-909 (Pubitemid 34438329)
32. Cree MG, Newcomer BR, Herndon DN, et al. PPAR-alpha agonism improves whole body and muscle mitochondrial fat oxidation, but does not alter intracellular fat concentrations in burn trauma children in a randomized controlled trial. Nutr Metab (Lond) 2007;4:9